Cidara Therapeutics Grants New Employee Stock Options
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a prominent biotechnology firm known for its innovative Cloudbreak platform, has recently executed an exciting equity incentive program for its new employee, Timothy Alefantis. This strategic move stems from the company’s Compensation and Human Capital Committee's decision to award significant stock options and restricted stock units (RSUs) totaling 27,000 shares. This package, established under the Cidara Therapeutics, Inc. 2020 Inducement Incentive Plan, positions the company for continued growth and competitiveness in the biotech sector.
Details of the Grant and Vesting Schedule
The stock options provided to Alefantis come with an exercise price set at $21.54 per share, which coincides with the company’s closing stock price at the time of the grant. Over a period of four years, these shares will vest, allowing a portion to be accessible to the employee at various milestones. Specifically, 25% of the shares will be vested on the one-year anniversary from the commencement date, while the remaining shares will vest in equal installments over the next three years. RSUs will also be vested annually, offering an additional layer of incentive aligned with the long-term goals of Cidara.
Ensuring Competitive Employee Engagement
The equity grant serves as an inducement for Alefantis to join Cidara, a strategic decision in alignment with Nasdaq Listing Rule 5635(c)(4). The Inducement Plan is particularly designed for attracting talent who are entering the company, either for the first time or after a bona fide period of non-employment. This approach demonstrates Cidara's commitment to fostering a motivated workforce, essential for driving future innovations in the biotechnology field.
About Cidara Therapeutics and Its Innovative Solutions
Cidara Therapeutics leverages its flagship Cloudbreak platform to create groundbreaking drug-Fc conjugates that combine targeted small molecules or peptides with a specially engineered human antibody fragment (Fc). Among its notable developments is CD388, which aims to provide a long-lasting solution against seasonal and pandemic influenza with just a single administration. With recent accolades like the Fast Track Designation awarded by the U.S. FDA, Cidara is well-positioned to address pressing global health challenges.
Recent Advancements and Future Directions
The company has made impressive strides, completing Phase 2b enrollment for its leading candidate in December. Additionally, Cidara has ventured into oncology treatment options, receiving IND clearance for CBO421, a promising therapy targeting CD73 in solid tumors. This continuous development underscores Cidara's adaptation to evolving medical needs and its commitment to delivering transformative therapies.
Links for More Information
For those interested in learning more about Cidara's innovative projects and offerings, detailed information is readily accessible through their official website, www.cidara.com.
Frequently Asked Questions
What types of awards were granted to Timothy Alefantis?
Timothy Alefantis received a non-qualified stock option award and restricted stock units (RSUs) totaling 27,000 shares.
What is the vesting schedule for the stock options?
The options will vest over four years, with 25% vesting after one year, and the remainder vesting in equal monthly installments thereafter.
What is the purpose of the Inducement Plan?
The Inducement Plan is designed to attract new employees or those returning after a break, enhancing the company's talent pool and competitive edge.
How does Cidara's lead candidate CD388 function?
CD388 is designed for the universal prevention of influenza by directly inhibiting viral proliferation and requires only a single dose for efficacy.
Where can I find more about Cidara's projects?
More information about Cidara's innovations and offerings can be found on their official website at www.cidara.com.
